Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP
Latest Information Update: 04 Jan 2024
Price :
$35 *
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 04 Jan 2022 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 07 Oct 2020 Planned End Date changed from 1 Nov 2019 to 1 Dec 2020.
- 07 Oct 2020 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2020.